Revolution Medicines' Rasonque targets the RAS protein driving 95% of pancreatic adenocarcinoma cases, offering a critical option after chemotherapy fails.

The FDA has approved daraxonrasib for previously treated metastatic pancreatic cancer. The targeted pill offers longer survival and fewer severe side effects in a disease with poor outcomes.